{'fraction_non_alphanumeric': 0.039337474120082816, 'fraction_numerical': 0.038302277432712216, 'mean_word_length': 5.0062111801242235, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Similar Efficacy of Ciclesonide Once Daily Versus Fluticasone Propionate Twice Daily in Patients with Persistent Asthma

This 12-week, double-blind, parallel-group study compared the efficacy and safety of once daily ciclesonide and twice daily fluticasone propionate in patients aged 12–75 years with persistent asthma. Patients were randomized to once-daily ciclesonide 80 μg (n = 278) or 160 μ g (n = 271), or twice daily fluticasone propionate 88 μ g (n = 259) (all ex-actuator). Significant improvements from baseline were seen in all three treatment groups for forced expiratory volume in 1 second, asthma symptom scores and rescue medication use (all p < 0.0001). Asthma exacerbation rates were low (each ciclesonide group, n = 2; fluticasone group, n = 1). Adverse event reporting indicated good tolerability. Once daily ciclesonide 80 μg or 160 μg showed comparable efficacy and tolerability to twice daily fluticasone propionate 88 μg in persistent asthma.